Prostate cancer is one of the most commonly diagnosed cancers in men in the United States and a major cause of cancer morbidity and mortality. The Johns Hopkins Prostate Cancer SPORE is focused on reducing prostate cancer incidence and mortality by translating new laboratory research discoveries into improvements in prostate cancer screening, detection, diagnosis, prevention, and treatment. Thus far, new prostate cancer biomarkers, inherited prostate cancer susceptibility genes, new approaches to prostate cancer immunotherapy, prostate-specific antigen-selective replication-restricted cytolytic adenoviruses, endothelin A receptor antagonists, prostate cancer-specific pro-drugs, and dietary approaches to prostate cancer prevention have all been introduced into clinical trials or population validation studies. This competitive renewal proposal contains six new Translational Research Projects, three Core Resources, two Career Development Projects, and two Developmental Research Projects. Research Project #1 aims to combine aptamer-targeted radiosensitizing interfering RNAs and radiation therapy, Project #2 considers the contributions of prostate-specific antigen itself to prostate cancer progression, Project #3 tests the enhancement of prostate cancer immunotherapy achievable with antibodies against auto-immune checkpoint regulators, Project #4 targets the development of histone deacetylase inhibitors as anti-angiogenic agents for prostate cancer, Project #5 pursues the discovery and validation of epigenetic biomarkers for prostate cancer progression, and Project #6 drives the development of new serum biomarkers for prostate cancer. Each of the Projects directs new scientific findings or insights toward human clinical trials or to population studies;each also features Co-Principal Investigators managing effective multidisciplinary translational research teams. The Research Projects are supported by an Administrative Core (A), which also manages inter-SPORE collaborations, a Tissue Archive Core (B), and a Biostatistics and Epidemiology Core (C).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058236-17
Application #
8116715
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Program Officer
Hruszkewycz, Andrew M
Project Start
1997-09-30
Project End
2013-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
17
Fiscal Year
2011
Total Cost
$2,185,002
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Pradhan, Anjan K; Talukdar, Sarmistha; Bhoopathi, Praveen et al. (2017) mda-7/IL-24 Mediates Cancer Cell-Specific Death via Regulation of miR-221 and the Beclin-1 Axis. Cancer Res 77:949-959
Zamboni, Camila G; Kozielski, Kristen L; Vaughan, Hannah J et al. (2017) Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma. J Control Release 263:18-28
Sharma, Anup; Mendonca, Janet; Ying, James et al. (2017) The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion. Mol Oncol 11:655-669
Winchester, Danyelle A; Till, Cathee; Goodman, Phyllis J et al. (2017) Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. Prostate 77:908-919
Guedes, Liana B; Almutairi, Fawaz; Haffner, Michael C et al. (2017) Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. Clin Cancer Res 23:4693-4703
Markowski, Mark C; Silberstein, John L; Eshleman, James R et al. (2017) Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol 2017:
Graham, Mindy Kim; Principessa, Lorenzo; Antony, Lizamma et al. (2017) Low p16(INK4a) Expression in Early Passage Human Prostate Basal Epithelial Cells Enables Immortalization by Telomerase Expression Alone. Prostate 77:374-384
Torres, Alba; Alshalalfa, Mohammed; Tomlins, Scott A et al. (2017) Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. J Mol Diagn 19:475-484
Lotan, Tamara L; Torres, Alba; Zhang, Miao et al. (2017) Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers. Oncotarget 8:22772-22782
Platz, Elizabeth A; Kulac, Ibrahim; Barber, John R et al. (2017) A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. Cancer Epidemiol Biomarkers Prev 26:1549-1557

Showing the most recent 10 out of 725 publications